Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Tirbanibulin (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Acronyms TIRBASKIN
- Sponsors Almirall S.A.
Most Recent Events
- 09 Jan 2024 Status changed from recruiting to completed.
- 01 Aug 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2023.
- 01 Aug 2023 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2023.